Polio, Chickenpox, Measles, Now Covid. It’s Time to Consult History on School Vaccine Mandates
As some states adopt covid vaccine requirements, not everyone agrees mandates for children are the way forward. Taking a page from history: We have two paths to putting the pandemic behind us: a quicker, more certain one of mandatory vaccination or a stuttering, drawn-out, likely more deadly affair.
La historia muestra que vacunar a los niños ayuda a prevenir brotes de enfermedades graves. ¿Qué pasará con covid?
Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
Analysis: A Procedure That Cost $1,775 in New York Was $350 in Maryland. Here’s Why.
The state’s unique health system controls what hospitals can charge for services.
The Checkup Is in the Mail? Soliciting Letter Carriers to Help Deliver Health Care
Here’s an out-of-the-box idea: Have letter carriers spend less time delivering mail and take time to perform home visits and basic health checks on the growing population of frail and elderly.
Análisis: ¿No quieres una vacuna? Prepárate para pagar más por tu seguro de salud
A pesar de que las compañías de seguros negocian precios más bajos y cubren gran parte del costo de la atención, los costos asociados al tratamiento de covid deberían ser un incentivo bastante aterrador.
Analysis: Don’t Want a Vaccine? Be Prepared to Pay More for Insurance.
Health insurers could do more to encourage vaccination, including letting the unvaccinated foot their bills.
Analysis: Necessary or Not, Covid Booster Shots Are Probably on the Horizon
In today’s pharmaceutical universe, a simple “safe and effective” determination by the Food and Drug Administration to approve a drug can be manipulated to sell products of questionable value. And drugmakers can profit handsomely.
Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
Analysis: Why We’ll Likely Never Know Whether a Covid Lab Leak Happened in China
If international scientific sleuths are hoping to see a lab log or find a whistleblower, that sort of information won’t be revealed. In China today, it is dangerous to say what you know if it challenges the official government narrative.